Elias J Jabbour, MD
M.D. Anderson Cancer Center
2
2
0
N/A
0
0
Research Impact
N/A
Research impact score
0
Total publications
0
Published trial results
0
Total citations
Drug Portfolio
Analytics
Trial Phases
Trial Status
Role Distribution
Activity Timeline
Clinical Trials (2)
Research Network
Collaboration Network
Research Areas & Affiliations
Therapeutic Areas
Affiliations
Similar Key Opinion Leaders
Discover other key opinion leaders with similar research profiles, therapeutic areas, and collaboration networks.
Farhad Ravandi-Kashani, MD
M.D. Anderson Cancer Center
Shared therapeutic areas:
Worked with same sponsors:
Elias Jabbour, MD
M.D. Anderson Cancer Center
Shared therapeutic areas:
Worked with same sponsors:
Elias Jabbour
M.D. Anderson Cancer Center
Shared therapeutic areas:
Worked with same sponsors:
Beata Holkova, MD
Massey Cancer Center
Shared therapeutic areas:
Brigitte C Widemann, M.D.
National Cancer Institute (NCI)
Shared therapeutic areas:
Jae Park, MD
Memorial Sloan Kettering Cancer Center
Shared therapeutic areas:
Worked with same sponsors:
Partow Kebriaei, MD
M.D. Anderson Cancer Center
Shared therapeutic areas:
Worked with same sponsors:
Ryotaro Nakamura
City of Hope Medical Center
Shared therapeutic areas:
Jorge Cortes, MD
M.D. Anderson Cancer Center
Shared therapeutic areas:
Worked with same sponsors:
Jianxiang Wang, Dr
Institute of Hematology & Blood Diseases Hospital, China
Shared therapeutic areas:
Publications (0)
No publications found for this investigator.
Clinical Trials (2)
Showing 2 of 2 trials
Phase II Study of the Combination of Subcutaneous Blinatumomab and Olverembatinib in Patients With Philadelphia Chromosome (ph)-Positive and/or BCR::ABL1 Positive Acute Lymphoblastic Leukemia (ALL)
A Phase IB Trial of Subcutaneous Blinatumomab in Combination With Revumenib for Patients With KMT2A-rearranged Acute Lymphoblastic Leukemia
All 2 trials loaded